Abstracts Archive - Page 1047 of 2425 - ACR Meeting Abstracts

Abstract Number: 636 • 2018 ACR/ARHP Annual Meeting
Remission/Low Disease Activity Is a Reasonable Treatment Target in Psa: Results from a Routine Care European Cohort of Psa Patients Treated with Ustekinumab or TNF Inhibitors
Laure Gossec^1,2, Paul Bergmans³, Kurt de Vlam⁴, Elisa Gremese⁵, Beatriz E. Joven⁶, Tatiana Korotaeva⁷, Michael Nurmohamed^8,9, Petros Sfikakis¹⁰, Stefan Siebert¹¹, Pavel Smirnov¹², Elke Theander¹³ and Josef S. Smolen¹⁴, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology, Sorbonne Université, Paris, France, ³Biometrics, Janssen-Cilag B.V., Breda, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, ⁸Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁹Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ¹⁰Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ¹¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Cardiff, United Kingdom, ¹²Biometrics, Janssen-Cilag B.V., Moscow, Russian Federation, ¹³Biometrics, Janssen-Cilag B.V., Solna, Sweden, ¹⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: The link between treatment recommendations for PsA (to aim for a state of remission or low disease activity (LDA))1,2 and patient-important outcomes has been…
Abstract Number: 637 • 2018 ACR/ARHP Annual Meeting
How to Define Remission and Low Disease Activity in Psoriatic Arthritis? an Analysis of 419 Patients with a Double Perspective, Based on Composite Scores and Patients’ and Physicians’ Perspectives
Clémence Gorlier¹, Deborah Puyraimond-Zemmour¹, Laura C. Coates², Ana-Maria Orbai³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder¹⁵, Inna Gaydukova¹⁶, Ennio Lubrano¹⁷, Pascal Richette¹⁸, M. Elaine Husni¹⁹, Maarten de Wit²⁰, Josef S. Smolen²¹ and Laure Gossec²², ¹Sorbonne Université, PARIS, France, ²University of Oxford, Oxford, United Kingdom, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁷Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁸Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ¹⁹Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²⁰Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²²Sorbonne Universités, Paris, France
Background/Purpose: Remission (REM) or minimal/low disease activity (LDA) is the treatment goal in Psoriatic Arthritis (PsA). There is no consensus on definitions of REM/LDA. Recently,…
Abstract Number: 638 • 2018 ACR/ARHP Annual Meeting
Diagnostic Delay and Associated Factors in Axial Spondyloarthritis across Europe. Results from the European Map of Axial Spondyloarthritis Survey
Laure Gossec¹, Marco Garrido-Cumbrera^2,3,4, Denis Poddubnyy^5,6, David Galvez-Ruiz^2,4, Christine Bundy⁷, Carlos Jesus Delgado Dominguez^2,4, Raj Mahapatra⁸, Pedro Plazuelo-Ramos³, Souzi Makri⁹ and Victoria Navarro-Compán¹⁰, ¹Sorbonne Universités, Paris, France, ²Health & Territory Research (HTR), Seville, Spain, ³Spanish Coordinator of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁴Universidad de Sevilla, Seville, Spain, ⁵German Rheumatism Research Centre, Berlin, Germany, ⁶Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁷Cardiff University, Cardiff, United Kingdom, ⁸Ankylosing Spondylitis International Federation (ASIF), London, United Kingdom, ⁹Cyprus League Against Rheumatism, Nicosia, Cyprus, ¹⁰Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain
Background/Purpose: Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease associated with a long diagnostic delay (DD); however, recent data suggests improvements1. The purpose was to…
Abstract Number: 639 • 2018 ACR/ARHP Annual Meeting
Is a Primary Good Response to Nsaids Predictive of the Subsequent Response to the First TNF Inhibitor in Patients with Early Axial Spondyloarthritis ?
Loukianos Couvaras¹, Daniel Wendling², Vanessa Pauly³, Vincent Pradel⁴, Anna Molto⁵, Pierre Lafforgue¹ and Thao Pham⁶, ¹Rheumatology, Aix-Marseille University, APHM, Marseille, France, ²service de rhumatologie, CHU J Minjoz, Besancon, France, ³Public Health, Aix-Marseille university, AP-HM, Marseille, France, ⁴Public Health, APHM, Marseille, France, ⁵Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁶Rheumatology Department, Aix-Marseille University, APHM, Marseille, France
Background/Purpose: Good response to NSAIDs is a SpA feature included in classification criteria for axial spondyloarthritis (axSpA). Among patients eligible for a TNF inhibitor (TNFi),…
Abstract Number: 640 • 2018 ACR/ARHP Annual Meeting
Increasing Rates of Arthroplasty for Psoriatic Arthritis in the United Kingdom between 1995 and 2010
Ryan Lewinson¹, Isabelle Vallerand², Jeremy LaMothe³, Laurie Parsons¹, Alexandra Frolkis⁴, Mark Lowerison², Scott Patten² and Cheryl Barnabe^2,5, ¹Dermatology, University of Calgary, Calgary, AB, Canada, ²Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Orthopaedic Surgery, University of Calgary, Calgary, AB, Canada, ⁴Internal Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Arthroplasty requirements among patients with psoriatic arthritis (PsA) are not well known. This information is of importance to clinical and policy stakeholders for health…
Abstract Number: 641 • 2018 ACR/ARHP Annual Meeting
Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis
Ali Duarte-Garcia¹, Lihi Eder², Alisa Stephens-Shields³, Niti Goel⁴, Maarten de Wit⁵, Dafna D Gladman⁶, Oliver FitzGerald⁷, Philip Helliwell⁸, Ying Ying Leung⁹, Philip J. Mease¹⁰, Ana-Maria Orbai¹¹, Beverly Shea¹², Vibeke Strand¹³, William Tillett¹⁴, Laura C. Coates¹⁵ and Alexis Ogdie¹⁶, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, ²Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ³Department of Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Kezar Life Sciences; Duke University School of Medicine, Durham, NC, ⁵EULAR standing committee of PARE, Zurich, Switzerland, ⁶Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁸LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁹North District Hospital, Hong Kong, China, ¹⁰Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ¹¹Johns Hopkins University School of Medicine, Baltimore, MD, ¹²University of Ottawa, Ottawa, ON, Canada, ¹³Stanford University School of Medicine, Palo Alto, CA, ¹⁴Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, ¹⁵University of Oxford, Oxford, United Kingdom, ¹⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Joint counts are central to the measurement of musculoskeletal disease activity in psoriatic arthritis (PsA). Few studies have addressed whether the three most commonly…
Abstract Number: 642 • 2018 ACR/ARHP Annual Meeting
Cost of Illness Analysis before and after Initiation of Tumour Necrosis Factor α Inhibitors in Patients with Axial Spondyloarthritis
Imke Redeker¹, Falk Hoffmann², Johanna Callhoff¹, Hildrun Haibel³, Joachim Sieper⁴, Angela Zink⁵ and Denis Poddubnyy⁴, ¹Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany, ²Department of Health Services Research, Carl von Ossietzky University, Oldenburg, Germany, ³Charité Universitätmedizin Berlin, Berlin, Germany, ⁴Rheumatology, Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁵Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany
Background/Purpose: Tumour necrosis factor-α inhibitors (TNFi) are an effective but rather expensive treatment option in axial spondyloarthritis (axSpA) patients who fail conventional treatment. The aim…
Abstract Number: 643 • 2018 ACR/ARHP Annual Meeting
Remission in Psoriatic Arthritis: Definition and Predictors
Samar AlHarbi¹, Justine Y. Ye², Ker-Ai Lee³, Vinod Chandran², Richard J. Cook³ and Dafna D Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: No validated definition of remission exists for psoriatic arthritis (PsA) to date. We previously identified 17.6% of our patients as having remission (no actively…
Abstract Number: 644 • 2018 ACR/ARHP Annual Meeting
Influence of Inflammation and Structural Damage on Global Functioning in Patients with Axial Spondyloarthritis – Using the ASAS Health Index in Routine Care
Uta Kiltz¹, Thomas Wiatr², Xenofon Baraliakos¹, Kirill Fedorov² and Jürgen Braun³, ¹Rheumatology, Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Ruhr-University Bochum, Bochum, Germany
Background/Purpose: To investigate the relationship between spinal mobility and self-report global functioning as assessed by the ASAS Health Index (ASAS HI), and to study the…
Abstract Number: 645 • 2018 ACR/ARHP Annual Meeting
Real World Secukinumab Study in Ankylosing Spondylitis and Psoriatic Arthritis – Comorbidities and Extraarticular Manifestations: Incidence and Status throughout a Non-Interventional Study in Germany
Uta Kiltz¹, Peter Kaestner², Holger Krauel², Ilka Schwarze³, Jan Brandt-Juergens⁴, Monika Maier-Peuschel⁵, Carolin Legeler⁵, Justyna Veit⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, ³Praxis internistische Rheumatologie, Leipzig, Germany, ⁴Rheumatology, Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) may suffer from extraarticular (EA) manifestations (uveitis, psoriasis) and have higher rates of comorbidities like…
Abstract Number: 646 • 2018 ACR/ARHP Annual Meeting
Do Ethnicity, Degree of Family Relationship, and the Spondyloarthritis Subtype in Affected Relatives Influence the Association between a Positive Family History for Spondyloarthritis and HLA-B27 Carriership? Results from the Worldwide ASAS Cohort
Miranda van Lunteren¹, Alexandre Sepriano^1,2, Robert B.M. Landewé^3,4, Joachim Sieper^5,6, Martin Rudwaleit^6,7, Désirée van der Heijde¹ and Floris van Gaalen¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal, ³Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁴Rheumatology, Zuyderland Hospital, Heerlen, Netherlands, ⁵German Rheumatism Research Centre, Berlin, Germany, ⁶Rheumatology, Charité Campus Benjamin Franklin, Berlin, Germany, ⁷Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) defines a positive family history (PFH) of spondyloarthritis (SpA) as presence of ankylosing spondylitis (AS), acute anterior…
Abstract Number: 647 • 2018 ACR/ARHP Annual Meeting
Validation of a New Electronic Spinal Mobility Index for Patients with Axial Spondyloarthritis Based on Inertial Motion Unit (IMU) Sensors
Philip Gardiner¹, Dawn Small², Eithne Boyle², Ann Marie Conlon², José António P. da Silva³, Joan Condell⁴, Antonio Cuesta-Vargas⁵, Eduardo Collantes-Estévez⁶ and Juan Luis Garrido-Castro⁷, ¹Rheumatology, Western Health and Social Care Trust, Londonderry, United Kingdom, ²Western Health and Social Care Trust, Londonderry, United Kingdom, ³Department of rheumatology, Centro Hospitalar e Universitário de Coimbra (SRHUC), Coimbra, Portugal, ⁴Ulster University, Coleraine, United Kingdom, ⁵University of Malaga, Malaga, Spain, ⁶Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁷IMIBIC, Cordoba, Spain
Background/Purpose: Spinal mobility is a major problem for people with axial spondyloarthritis (axSpA). The BASMI has been widely used for measuring spinal mobility but it…
Abstract Number: 648 • 2018 ACR/ARHP Annual Meeting
Performance of an Online Self-Referral Questionnaire Compared to a Physician-Based Referral Approach to Identify Patients with a High Probability of Axial Spondyloarthritis: Results from the Optiref Study
Fabian Proft¹, Laura Spiller¹, Mikhail Protopopov¹, Valeria Rios Rodriguez¹, Burkhard Muche¹, Judith Rademacher¹, Susanne Lueders², Anne-Katrin Weber¹, Inge Spiller¹, Joachim Sieper^3,4 and Denis Poddubnyy^3,4, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ³German Rheumatism Research Centre, Berlin, Germany, ⁴Charité Universitätsmeidzin Berlin, Berlin, Germany
Background/Purpose: The diagnostic delay in axial spondyloarthritis (axial SpA) has been reported to be 9 years and still remains unacceptably high. One of the major…
Abstract Number: 649 • 2018 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on a Quick Quantitative CRP Assay Performs Similarly Well to ASDAS Based on Conventional CRP in Patients with Axial Spondyloarthritis
Fabian Proft¹, Burkhard Muche¹, Laura Spiller¹, Valeria Rios Rodriguez¹, Judith Rademacher¹, Anne-Katrin Weber¹, Susanne Lueders², Mikhail Protopopov¹, Inge Spiller¹, Joachim Sieper³ and Denis Poddubnyy^3,4, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ³Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁴German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite index to assess disease activity in patients with axial spondyloarthritis (axSpA). According to the…
Abstract Number: 650 • 2018 ACR/ARHP Annual Meeting
Can Disease Activity in Patients with Psoriatic Arthritis be Adequately Assessed By a Modified Disease Activity Index for Psoriatic Arthritis (DAPSA) Based on 28 Joints?
Brigitte Michelsen^1,2, Joseph Sexton¹, Josef S. Smolen³, Daniel Aletaha⁴, Niels Steen Krogh⁵, Désirée van der Heijde⁶, Tore Kvien⁷ and Merete Lund Hetland^8,9, ¹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Division of Rheumatology, Department of Internal Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Leiden University Medical Centre, Leiden, Netherlands, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, The DANBIO Registry, Glostrup, Denmark, ⁹University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Many registries routinely collect only 28 joint count, although 66/68 joint count has higher face validity in PsA. We aimed to compute and test…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].